Clinical Trial Update: Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of incobotulinumtoxinA (Xeomin) for Parkinson's tremor; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Xeomin (incobotulinumtoxinA) (incobotulinumtoxinA)

Snippet

Sponsor: Yale University | Conditions: Parkinson, Tremor | Phase 2 | Status: COMPLETED | Results posted: 2016-03-14